click on circles to display study description...
anticoagulant, curative dose (n=311) vs. anticoagulant, prophylactic dose (n=304)
randomized controlled trial
therapeutic anticoagulation
in-hospital oral rivaroxaban (20 mg or 15 mg daily) for stable patients, or initial subcutaneous enoxaparin (1 mg/kg twice per day) or intravenous unfractionated heparin (to achieve a 0·3–0·7 IU/mL anti-Xa concentration) for clinically unstable patients, followed by rivaroxaban to day 30.
prophylactic anticoagulation
standard in-hospital enoxaparin or unfractionated heparin
COVID 19 hospitalized
open-label
31 hospitals in Brazil
anticoagulant, curative dose (n=1190) vs. anticoagulant, prophylactic dose (n=1054)
randomized controlled trial
therapeutic-dose anticoagulation with heparin
usual care pharmacological thromboprophylaxis
COVID-19 mild to moderate
open-label
prematurely discontinued after a planned adaptive analysis of data from 1398 patients showed that the prespecified stopping criteria for superiority of therapeutic-dose anticoagulation had been reached in both the high and low d-dimer cohorts
anticoagulant, curative dose (n=191) vs. anticoagulant, prophylactic dose (n=191)
randomized controlled trial
full-dose anticoagulation
standard-dose prophylactic anticoagulation
COVID-19 severe or critically
open label
34 centers, United States
2x2 factorial deisgn with clopidogrel or no antiplatelet therapy; recruitment was stopped early in 03/2022 (∼50% planned recruitment) due to waning ICU-level COVID-19 rates
anticoagulant, curative dose (n=591) vs. anticoagulant, prophylactic dose (n=616)
randomized controlled trial
therapeutic anticoagulation with heparin
Therapeutic anticoagulation was administered according to local site protocols for the treatment of acute venous thromboembolism for up to 14 days or recovery
pharmacological thromboprophylaxis as per local usual care
COVID-19 severe or critically
open-blind
NCT02735707, NCT04505774, NCT04359277, NCT04372589
powered by vis.js Network
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -
An extraction panel is open